Keros Therapeutics Stock Analysis

Keros Stock Analysis Notes

About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.8. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Keros Therapeutics recorded a loss per share of 5.0. The entity had not issued any dividends in recent years. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Keros Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 97 people. To find out more about Keros Therapeutics contact Jasbir Seehra at 617 314 6297 or learn more at https://www.kerostx.com.

Keros Therapeutics Investment Alerts

Keros Therapeutics Upcoming and Recent Events

Keros Largest EPS Surprises

View All Earnings Estimates

Keros Therapeutics Environmental, Social, and Governance (ESG) Scores

Keros Stock Institutional Investors

Note, although Keros Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Keros Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 455.11 M.

Keros Profitablity

Management Efficiency

Keros Therapeutics has return on total asset (ROA) of (0.2673) % which means that it has lost $0.2673 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4146) %, meaning that it created substantial loss on money invested by shareholders. Keros Therapeutics' management efficiency ratios could be used to measure how well Keros Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2025. Return On Capital Employed is likely to drop to -0.38 in 2025. At this time, Keros Therapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 28.3 M in 2025, whereas Return On Tangible Assets are likely to drop (0.32) in 2025.

Technical Drivers

As of the 24th of March, Keros Therapeutics secures the Standard Deviation of 3.67, mean deviation of 2.63, and Risk Adjusted Performance of (0.16). Keros Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Keros Therapeutics market risk adjusted performance and treynor ratio to decide if Keros Therapeutics is priced some-what accurately, providing market reflects its recent price of 11.45 per share. Given that Keros Therapeutics has information ratio of (0.18), we recommend you to check Keros Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Keros Therapeutics Price Movement Analysis

Keros Therapeutics Insider Trading Activities

Keros Therapeutics Outstanding Bonds

Keros Therapeutics Predictive Daily Indicators

Keros Therapeutics Corporate Filings

Keros Therapeutics Forecast Models

Keros Therapeutics' time-series forecasting models are one of many Keros Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Keros Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Keros Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Keros shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Keros Therapeutics. By using and applying Keros Stock analysis, traders can create a robust methodology for identifying Keros entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Keros analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Keros analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Keros Therapeutics stock analysis indicators help investors evaluate how Keros Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Keros Therapeutics shares will generate the highest return on investment. By understating and applying Keros Therapeutics stock analysis, traders can identify Keros Therapeutics position entry and exit signals to maximize returns.

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.